dc.contributor.author | Celebier, Mustafa | |
dc.contributor.author | Kaynak, Mustafa Sinan | |
dc.contributor.author | Altinoz, Sacide | |
dc.contributor.author | Sahin, Selma | |
dc.date.accessioned | 2019-12-16T10:29:10Z | |
dc.date.available | 2019-12-16T10:29:10Z | |
dc.date.issued | 2014 | |
dc.identifier.issn | 1521-298X | |
dc.identifier.uri | https://doi.org/10.14227/DT210414P56 | |
dc.identifier.uri | http://hdl.handle.net/11655/20064 | |
dc.description.abstract | Rivaroxaban is an oral anticoagulant that is the first available orally active direct Factor Xa inhibitor. In this study, a UV spectrophotometric method was developed for the determination of rivaroxaban content in pharmaceutical formulations and the amount of rivaroxaban released in tablet dissolution studies. The dissolution profile of rivaroxaban was successfully determined with the validated method. | |
dc.language.iso | en | |
dc.publisher | Dissolution Technologies, Inc | |
dc.relation.isversionof | 10.14227/DT210414P56 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Uv Spectrophotometric Method For Determination Of The Dissolution Profile Of Rivaroxaban | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | Dissolution Technologies | |
dc.contributor.department | Analitik Kimya | |
dc.identifier.volume | 21 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 56 | |
dc.identifier.endpage | 59 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |